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Abstract
Multiple myeloma (MM) is a genetically heterogeneous disease, which to date remains fatal. Finding a common mechanism
for initiation and progression of MM continues to be challenging. By means of integrative genomics, we identified an
underexpressed gene signature in MM patient cells compared to normal counterpart plasma cells. This profile was enriched
for previously defined H3K27-tri-methylated genes, targets of the Polycomb group (PcG) proteins in human embryonic
fibroblasts. Additionally, the silenced gene signature was more pronounced in ISS stage III MM compared to stage I and II.
Using chromatin immunoprecipitation (ChIP) assay on purified CD138+ cells from four MM patients and on two MM cell
lines, we found enrichment of H3K27me3 at genes selected from the profile. As the data implied that the Polycomb-
targeted gene profile would be highly relevant for pharmacological treatment of MM, we used two compounds to
chemically revert the H3K27-tri-methylation mediated gene silencing. The S-adenosylhomocysteine hydrolase inhibitor 3-
Deazaneplanocin (DZNep) and the histone deacetylase inhibitor LBH589 (Panobinostat), reactivated the expression of genes
repressed by H3K27me3, depleted cells from the PRC2 component EZH2 and induced apoptosis in human MM cell lines. In
the immunocompetent 5T33MM in vivo model for MM, treatment with LBH589 resulted in gene upregulation, reduced
tumor load and increased overall survival. Taken together, our results reveal a common gene signature in MM, mediated by
gene silencing via the Polycomb repressor complex. The importance of the underexpressed gene profile in MM tumor
initiation and progression should be subjected to further studies.
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Introduction
Multiple myeloma (MM) remains a fatal hematopoietic
malignancy. MM is characterized by the clonal expansion of
tumor cells with plasma cell features in the bone marrow and is
considered a genetically heterogeneous disease [1]. Although the
predominant translocations in MM do not fully explain the
pathogenesis of the malignant plasma cell, the identification of
genetic entities has facilitated the development of targeted therapy,
such as FGFR3-kinase inhibitors in t(4;14) MM [2]. However,
such treatment does not apply to all MM patients. New
therapeutic strategies targeting common pathogenetic events in
MM are therefore imperative.
An emerging strategy to fight cancer complexity is to establish
gene expression profiles and connect them to specific signaling
pathways contributing to the disease [3]. In MM, gene expression
profiles have, in some cases, been linked to an underlying genetic
event such as a translocation to the immunoglobulin heavy-chain
locus or hyperdiploidy [4,5]. In further attempts to dissect the
disease phenotype, gene expression profiles have been used to
refine the underlying mechanisms in molecular subsets, to discover
predictors of drug response and identify novel drug targets
[6,7,8,9]. However, it still remains unclear how MM, although
phenotypically representing mature plasmablasts/plasma cells,
preserves the capacity of self-renewal and whether this capacity
may be identified as a common gene expression signature.
Recently, components of the Polycomb group (PcG) proteins
have gained a wide interest as prominent players in carcinogenesis
[10,11]. The PcG proteins function in large multimeric complexes,
of which the Polycomb repressive complexes PRC1 and PRC2 are
most well characterized. The PRC2 core complex consists of EED,
SUZ12, RBAP48 and the catalytic subunit EZH2 [12]. PcG
mediated gene repression requires a complex series of events,
initiated by the recruitment of PRC2 to target genes resulting in
the tri-methylation of histone H3K27, which then preserves
silencing of the transcriptional program through consecutive cell
divisions [13]. PcG mediated silencing is also suggested to
predispose target genes to DNA-methylation in various cancers
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11483[14,15,16] consistent with the observation that the PRC2 complex
interacts with DNMT1 and DNMT3A and B [17]. However, PcG
mediated repression may also constitute an independent mecha-
nism of silencing for some cancer genes, in the absence of DNA-
methylation [18].
In the present study integrative genomics was used to define the
nature of the underexpressed gene expression profile in MM when
compared to normal plasma cells. The identified gene signature
significantly correlated to defined Polycomb target genes [19] and
was more pronounced in advanced stages of the disease.
Enrichment of H3K27me3 at genes found in the profile was
confirmed by chromatin immunoprecipitation (ChIP) assay in four
newly diagnosed MM patients and two MM cell lines. The S-
adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin
(DZNep) and the histone deacetylase inhibitor LBH589 (Panobi-
nostat) reactivated the genes repressed by H3K27me3, depleted
cells of the PRC2 component EZH2, reduced proliferation and
increased apoptosis in human MM cell lines. Using the
immunocompetent 5T33MM in vivo model we show gene
upregulation, reduction of tumor load and increased overall
survival by LBH589. Collectively, our results point to a common
gene expression signature in MM mediated by gene silencing via
the PRC2 complex. Unraveling the underlying molecular
mechanisms and the biological significance of reactivating the
genes found in this signature may have new therapeutic
implications.
Results
H3K27-tri-methylation is a common denominator for the
underexpressed genes in multiple myeloma (MM)
Publicly available gene expression data sets [5,7,20] were
analyzed in an integrative genomics approach to identify unifying
denominators among genes underexpressed in multiple myeloma
(MM). Using the data-mining platform Oncomine [21] a strong
connection between genes underexpressed in patients with MM
(compared to normal bone marrow) and genes previously
described as H3K27me3 targets in human embryonic fibroblasts
[19] was discovered (Figure 1A, for a complete gene list see Table
S1). The H3K27me3 target genes were also overrepresented
among genes underexpressed in MGUS patients (Figure 1B) and
strongly associated with decreased expression in ISS stage III MM
(Figure 1C), compared to stage I and II (Figure 1D). Consistent
with this, overexpression of the PRC2 components EZH2, SUZ12
and EED was significantly correlated with the establishment and
progression of MM (Figure S1A–C).
Polycomb target genes are H3K27 tri-methylated in
patient MM cells and MM cell lines
Having established that the underexpressed gene profile in MM
significantly overlaps with defined Polycomb target genes, the
PRC2-mediated tri-methylation of histone H3 lysine 27 was
analyzed by chromatin immunoprecipitation (ChIP) in four newly
diagnosed MM patients (Figure 2A–D). Considering the limited
availability of patient material, enrichment for the negative
H3K27-tri-methylation and positive H3K9-acetylation marks
was analyzed in the RPMI 8226 (Figure 2E) and U-266-1984
(Figure 2F) MM cell lines. The chromatin modifications were
determined at five PRC2 targets commonly underexpressed in
MM (CIITA, CXCL12, GATA2, CDH6 and ICSBP/IRF8;
Figure S2A–C). The selected genes were then additionally
confirmed to be underexpressed in MM compared to normal
counterpart plasma cells in an independent data set [22]
(GSE6477, Figure S3). The INK4A/p16 gene was also included,
as a previously reported target of the Polycomb group (PcG)
proteins [23]. The actively transcribed genes RPL30 and GAPDH
were used as control genes for the lack of H3K27-tri-methylation
and presence of acetylation on histone H3 lysine 9.
Consistent with the role for Polycomb-mediated silencing,
t h ea n a l y z e dg e n e sw e r ef o u n de n r i c h e df o rH 3 K 2 7 - t r i -
methylation in the four MM patient samples (Figure 2A–D)
and both MM cell lines RPMI 8226 (Figure 2E) and U-266-
1984 (Figure 2F). These genes also lacked the positive
chromatin acetylation mark at H3K9 in both MM cell lines.
An exception to this was the ICSBP/IRF8 gene, which was
clearly enriched for H3K27-tri-methylation in two of the four
patients and the U-266-1984 cell line, whereas in the RPMI
8226 cells carried both the positive and negative mark. The
CIITA gene lacked clear enrichment in one of the patients and
the CXCL12 gene carried the positive H3K9-acetylation mark
in the RPMI 8226 cells and the negative H3K27-tri-methyl-
ation mark in the U-266-1984 cells.
The S-adenosylhomocysteine hydrolase inhibitor 3-
Deazaneplanocin (DZNep) and the histone deacetylase
inhibitor LBH589 reactivate Polycomb target genes in
MM cell lines
We next investigated the possibility of reactivating the genes
enriched for H3K27-tri-methylation. The expression of the genes
selected from the integrative genomics profile was analyzed after
treatment with the chemical inhibitors, DZNep and LBH589, in
the RPMI 8226 and U-266-1984 cell lines. RPMI 8226 and U-
266-1984 were treated with 10 mM DZNep and 20 nM LBH589
and the expression of CIITA, CXCL12, GATA2, CDH6, ICSBP/
IRF8 and INK4A was analyzed using Q-RT-PCR after 6, 24, 48
and 72 hours.
LBH589 (Figure 3A and 3B) was more potent and led to a
higher increase in mRNA levels at earlier time points in both cell
lines, whereas, DZNep (Figure 3C and 3D) increased mRNA
levels to a lesser extent and at later time points. Changes in gene
expression varied between the cell lines and had slightly different
kinetic profiles. CIITA mRNA expression in RPMI 8226
increased after DZNep and LBH589 treatment. In U-266-1984,
CIITA expression gradually increased only by DZNep. In RPMI
8226, CXCL12 gene expression was upregulated only after
DZNep treatment. GATA2 responded strongly to both drugs in
both cell lines. The CDH6 mRNA level was increased by both
DZNep and LBH589 in RPMI 8226. ICSBP/IRF8 expression
increased gradually by DZNep in both cell lines; LBH589
strongly increased ICSBP/IRF8 mRNA levels only in U-266-
1984. INK4A/p16 responded weakly to both drugs in both cell
lines.
CXCL12 and CDH6 mRNA levels were detected at very late
amplification cycles in U-266-1984 and were not amenable to
analysis.
Both DZNep and LBH589 deplete EZH2 protein levels in
MM cell lines
EZH2 is the catalytically active subunit of PRC2 responsible for
the establishment of tri-methylation at histone H3 lysine 27 that is
associated with gene silencing [24]. The two chemical inhibitors,
the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplano-
cin (DZNep) and the histone deacetylase inhibitor LBH589, are
reported to deplete EZH2 protein levels and reduce survival in
cancer cells [25,26].
The MM cell lines, RPMI 8226 and U-266-1984 were treated
with DZNep at 0.5, 2.5 and 10 mM or LBH589 at 4, 10, 20 nM
Polycomb Silencing in MM
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EZH2 protein levels measured by Western blotting analysis was
observed in a dose-dependent manner for both drugs in both cell
lines (Figure S4A–D). Treatment with 10 mM DZNep for 6, 24, 48
and 72 hours led to a gradual depletion of EZH2 protein in both
the RPMI 8226 and the U-266-1984 cells (Figure 4A and 4B).
Additionally, the EZH2 protein level was reduced after treatment
with 20 nM LBH589 with the strongest reduction observed at the
latest time point of treatment, 48 hours for U-266-1984, and
72 hours for RPMI 8226 (Figure 4C and 4D).
Figure 1. H3K27me3 targets are underexpressed in multiple myeloma (MM) and monoclonal gammopathy of undetermined
significance (MGUS). The H3K27me3 target genes (n=2390) were defined by Bracken et al. [19] in embryonic fibroblasts and found to be
statistically associated to underexpressed genes in MM and MGUS using Oncomine. (A): The top 10% underexpressed genes [7] (n=456) in MM
patients (n=74) compared to plasma cells (n=37) and tonsillar tissue (n=37) showed significant (p=2.13610
29) overlap with the H3K27me3 target
genes. (B): The top 10% underexpressed genes [20] (n=1907) in MGUS patients (n=44) compared to normal bone marrow (n=22) showed
significant (p=5.5610
210) overlap with the H3K27me3 target genes. (C): The top 10% underexpressed genes [5] (n=1242) in MM stage III (n=34)
compared to MM stage I and stage II (n=68) showed significant (p=1.3610
233) overlap with the H3K27me3 target genes. (D): H3K27me3 target
genes expression during MM progression [5].
doi:10.1371/journal.pone.0011483.g001
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PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11483Figure 2. Polycomb target genes are enriched for H3K27-tri-methylation in MM patient cells and MM cell lines. Chromatin
immunoprecipitation (ChIP) assay using (A)–(D): antibody against H3K27-tri-methylation in purified CD138+ cells from MM patients; (E) and (F):
antibodies against H3K27-tri-methylation and H3K9-acetylation in RPMI 8226 and U-266-1984 cells. The RPL30 and GAPDH genes were used as a
negative control for H3K27-tri-methylation and a positive control for H3K9-acetylation. The CIITA, CXCL12, GATA2, CDH6 and ICSBP genes were
selected from the integrative genomics profile. * The INK4A gene was selected from the literature. Immunoprecipitated DNA was analyzed using real-
time qPCR. Specific signal was calculated as fold change between signal and background (IgG) noise normalized to percent input. (E) and (F): Error
bars represent SD from three independent biological experiments.
doi:10.1371/journal.pone.0011483.g002
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PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11483Figure 3. The expression of H3K27-tri-methylated genes is reactivated by DZNep and LBH589 in MM cell lines. The RPMI 8226 cells (A)
and (C), and the U-266-1984 cells (B) and (D) were treated with DZNep (10 mM) or LBH589 (20 nM) for 6, 24, 48 and 72 hours. Fold difference in
expression was calculated relative to the untreated cells. GAPDH was used as a reference gene. Error bars represent SD from three independent
biological experiments.
doi:10.1371/journal.pone.0011483.g003
Figure 4. DZNep and LBH589 deplete EZH2 protein level in MM cell lines. (A) and (B): The RPMI 8226 cells (A) and the U-266-1984 cells (B)
were treated with DZNep (10 mM) for 6, 24, 48 and 72 hours. (C) and (D): The RPMI 8226 cells (C) and the U-266-1984 cells (D) were treated with
LBH589 (20 nM) for 6, 24, 48 and 72 (RPMI 8226) or 6, 24 and 48 hours (U-266-1984). Western blot was performed using a specific antibody against
EZH2. Actin was used to control for equal loading.
doi:10.1371/journal.pone.0011483.g004
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of MM cell lines
To elucidate the effects of Polycomb inhibitors on the growth
and survival of MM cells, RPMI 8226 and U-266-1984 were
treated with DZNep or LBH589 for 6, 24, 48 and 72 hours and
cell growth was analyzed by the resazurin assay. Both treatments
decreased the relative number of viable MM cells in a dose-
dependent manner (Figure S5A and S5B). On the contrary,
treatment with the same concentrations of both drugs of normal
peripheral blood mononuclear cells (PBMC) and normal human
fibroblast SK 1064 cells showed no decrease in cell viability
(Figure S6A and S6B). Treatment with 10 mM DZNep exhibited
over 60% growth inhibition in RPMI 8226 and over 40% in U-
266-1984 at 72 hours of treatment, compared to the untreated
cells (Figure 5A). Treatment with 20 nM LBH589 was more
potent in reducing the relative amount of viable cells and led to a
70% and 60% growth inhibition at 72 hours in RPMI 8226 and
U-266-1984, respectively (Figure 5B).
To further characterize the effect of DZNep and LBH589 in
reducing the number of viable cells, induction of apoptosis was
quantified by AnnexinV/PI staining using FACS analysis. At
72 hours DZNep treatment increased the fraction of late
apoptotic/necrotic cells in RPMI 8226 and U-266-1984 more
than two fold (Figure 5C). Treatment with LBH589 was more
potent in inducing apoptosis and led to approximately 3 fold
increase of AnnexinV/PI positive apoptotic cells in RPMI 8226
and greater than 3 fold increase in U-266-1984 cells at 72 hours
(Figure 5D).
LBH589 treatment upregulates Polycomb target gene
expression, decreases tumor load and promotes survival
in the murine 5T33MM model
Similar to human MM cell lines, treatment with LBH589
induces decreased DNA synthesis, cell cycle arrest and apoptosis in
5T33MM cells in vitro (data not shown). Here, the murine
syngeneic immunocompetent 5T33MM model [27,28] was used
to evaluate the effect of LBH589 treatment in vivo. The C57BL/
KalwRij mice were injected with the myeloma 5T33MM cells and
after 14 days subjected to treatment with LBH589 (10 mg/kg) as
described in materials and methods. After 5 days of treatment
mice were sacrificed and their BM harvested. To confirm the
reactivation of CIITA and CXCL12 gene expression in the in vivo
5T33MM model, RNA was extracted from the total BM fraction
and from CD11b-depleted fraction of BM cells. We found that
Figure 5. DZNep and LBH589 reduce growth and induce apoptosis in MM cell lines. (A) and (B): U-266-1984 and RPMI 8226 cells were
treated for 6, 24, 48 and 72 hours with DZNep (10 mM) or LBH589 (20 nM) followed by a resazurin assay. At least 2 independent experiments were
performed in triplicates, data is presented as mean percentage of control 6SD. (C) and (D): U-266-1984 and RPMI 8226 were treated with DZNep
(10 mM) and LBH589 (20 nM) for 72 hours followed by AV/PI staining and flow cytometry analysis. At least 2 independent experiments per cell line
were performed; data is presented as mean percentage apoptotic cells 6SD.
doi:10.1371/journal.pone.0011483.g005
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CD11b-depleted bone marrow cells (Figure 6A), whereas
CXCL12 was upregulated both in the crude BM cell fraction
and in the CD11b-depleted cells (Figure 6B). Secondly, the effect
of LBH589 as single drug treatment (continuous treatment) was
determined on the in vivo tumor burden. The C57BL/KalwRij
mice were injected with 5T33MM cells and the effect of LBH589
treatment compared to a vehicle treatment was analyzed. A
significant decrease (p,0.0001) in the tumor load after LBH589
treatment was determined by the amount of detected paraprotein
(M spike, Figure 6C) and the percentage of MM positive cells in
isolated bone marrow cells (Figure 6D). Finally, LBH589
Figure 6. LBH589 upregulates gene expression, reduces tumor load and increases survival in the 5T33MM mice model. (A) and (B): At
day 0 C57BL/KalwRij mice were injected with 0.5610
6 5T33MM cells. After 14 days mice were either assigned to a treatment group receiving 10 mg/
kg LBH589 (n=4; daily i.p. injection) or to a vehicle group receiving 0.9% NaCl solution (n=4; daily i.p. injection). After 5 days of treatment mice were
sacrificed, BM harvested and a negative selection for CD11b positive cells performed. CIITA and CXCL12 fold difference in gene expression was
calculated relative to the vehicle by Q-RT-PCR. GAPDH was used as a reference gene. The error bars represent SEM from two independent Q-RT-PCR
runs. Each group contained one mouse, excluding the vehicle non-depleted, which contained two mice. (C) and (D): Mice were treated as described
above, with the difference that mice were either assigned to a treatment group receiving 10 mg/kg LBH589 (n=10; daily i.p. injection), to a vehicle
group receiving 0.9% NaCl solution (n=10; daily i.p injection) or to an untreated, disease-free group (n=10) as a control group at day 0. The animals
were sacrificed when the vehicle group showed signs of morbidity. Tumor load as determined by serum electrophoresis (C) and tumor load as
determined by May Gru ¨nwald-Giemsa staining of BM cytospin samples (D) Mean values 6 SD for groups of 10 mice are shown (*p,0.0001). (E)
Survival was studied using the Kaplan-Meier analysis method. Mice were treated as described above with the exception that treatment continued
until each animal showed signs of morbidity. Each group contained 12 mice (p,0.0003).
doi:10.1371/journal.pone.0011483.g006
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5T33MM mice, as displayed by the Kaplan-Meier survival curve
(Figure 6E).
Discussion
The genetic heterogeneity of multiple myeloma (MM) [1] has
hindered the identification of the mechanisms underlying its
pathogenesis and hence, MM remains a fatal disease. Both the
translocations to the immunoglobulin heavy chain (IgH) locus and the
chromosomal trisomies observed in MM fail to explain a common
origin of the disease and to provide a universal MM drug target. Gene
expression profiles have provided clues of the importance of previously
unrecognized signaling pathways in MM such as the NF-kB pathway
[6,8], but to date have mainly focused on subdividing MM into
genetic entities for prognostic or therapeutic purposes [9,20]. Thus,
the question remains if a common denominator for myeloma
development and tumor maintenance exists.
By means of integrative genomics we identified a set of
underexpressed genes in MGUS and MM patient cells relative
to normal bone marrow plasma cells and total bone marrow cells,
respectively. These genes have also been previously described as
targets of the Polycomb group (PcG) proteins in human embryonic
fibroblasts [19]. Importantly, the suppression of the genes found in
the profile was more pronounced in the advanced stages (ISS stage
III compared to stage II and I) of MM progression.
The presence of tri-methylation at histone H3 lysine 27 using
chromatin immunoprecipitation (ChIP) was determined for several
genes found in the profile in four MM patient samples, and two
MM cell lines RPMI 8226 and U-266-1984. Among the four
patients the genes selected from the integrative genomics approach
were consistently enriched for H3K27me3. In addition, simulta-
neous enrichment for the negative H3K27me3 and lack of the
H3K9-acetylation mark associated with an active transcription,
suggested active Polycomb-mediated silencing also in the two MM
cell lines. Notably, among the genes found in the expression
profile, and associated with H3K27me3, was the major histocom-
patibility (MHC) class II transactivator (CIITA) gene. CIITA is the
master regulator of MHC class II expression. Underexpression of
CIITA and thus of MHC II genes in MM has been described as a
mechanism to escape the immune response [29]. Independently,
Polycomb silencing of CIITA is described in uveal melanoma [30].
Another gene present in the profile was ICSBP/IRF8, which
frequently displays low levels of expression in patient plasma cells
and MM cell lines. This silencing mechanism is attributed to DNA
methylation of the ICSBP/IRF8 gene in 8 out of 10 MM cell lines,
including U-266-1984, whereas the frequency is lower in CD138+
selected primary MM cells with only 1 out of 9 being methylated
[31]. In the present study ICSBP/IRF8 was associated with
H3K27me3-mediated silencing in 3 out of 4 patients and the U-
266-1984 cell line. Interestingly, DNA methyltransferases are
known to be associated with the PRC2 complex [17], and thus
DNA methylation following Polycomb-mediated gene silencing is
suggested to contribute to permanent transcriptional repression in
cancer [14,15,16,18]. Hence, PcG mediated repression may be
sufficient, and in some cases precede DNA methylation and
explain the observed ICSBP/IRF8 silencing in MM patients
where DNA methylation is not detected. Our results are also
consistent with a previous study suggesting EZH2 as an oncogene
in MM, where it is often overexpressed and contributes to cell
survival [32]. An alternative mechanism for the deregulation of
Polycomb control of gene expression in MM was recently
suggested by the finding of prevalent mutations in the H3K27-
demethylase UTX [33].
The identification of the Polycomb repression gene profile based
on differentially expressed genes in MM patient cells, strongly
suggests that this profile is a common feature among the tumor
cells, rather than representing a specific subpopulation. Thus, an
emerging question is if targeting the common denominator for the
observed gene silencing can be used in the treatment of MM.
Epigenetic gene silencing is an attractive drug target due to the fact
it can be reverted. However, Polycomb targets are not uniformly
reactivated solely by depleting cells of PcG proteins using siRNA
interference [18,19,26,34]. In this study, two chemical inhibitors,
the global histone methylation inhibitor 3-Deazaneplanocin
(DZNep) [26,35] and the histone deacetylase inhibitor LBH589,
were successfully used to reactivate selected genes from the profile,
which carried the H3K27me3 mark, including CIITA and
INK4A/p16. Moreover, gene upregulation by LBH589 treatment
in vivo was also observed in the 5T33MM model of MM. In
addition to their role on global chromatin modifications and their
ability to reactivate Polycomb-silenced genes, DZNep and
LBH589 have also been reported to deplete EZH2 protein from
AML and breast cancer cells [25,26]. Similarly, both DZNep and
LBH589 depleted EZH2 protein also from MM cells. According
to recent data LBH589 treatment of cancer cells leads to ubiquitin-
dependent degradation of DNMT1 [36]. However, further studies
are needed to clarify whether a similar mechanism may contribute
to the protein downregulation of EZH2 in MM cells.
In addition to the reactivation of the Polycomb-target genes
both DZNep and LBH589 reduced viability and induced
apoptosis in two MM cell lines. As LBH589 has an advantageous
efficiency at nanomolar concentrations and is currently in phase I
and II clinical trials for several hematologic malignancies including
MM [37]; its effects on MM growth were evaluated also in vivo
using the murine 5T33MM model. Treatment with LBH589
significantly decreased tumor load and levels of paraprotein.
Additionally, LBH589 prolonged survival in the murine myeloma
5T33MM model. Thus, our data strongly supports the use of
LBH589 in the clinics and provides and alternative mechanism for
its antitumor action. Although limited effects of LBH589 single
administration have been reported, LBH589 is currently in phase I
clinical trials in combinatorial regimens for relapsed MM [38] due
to the fact that it is able to overcome drug resistance in MM cell
lines and cells from patients with refractory disease [39]. Recently,
a combination of both LBH589 and DZNep was reported to be an
effective therapy in a mice model of AML [40]; however data from
clinical studies has not yet been presented.
Taken together, our results with MM cell lines and fresh MM
biopsy cells are in agreement with several recent genome-wide
studies implicating Polycomb-mediated gene silencing in the
development of other types of malignancy [10,11]. During
embryogenesis the PcG proteins constitute an important part of
the epigenetic memory by repressing lineage-specific developmen-
tal genes. During normal differentiation PcG proteins become
redistributed whereby lineage-specific genes are expressed and
pluripotency genes become silenced [41,42,43]. The fact that an
epigenetic mark maintaining self-renewal in embryonic stem cells
is found in cancer supports the hypothesis that cancer cells share
features with normal stem cells. This observation has previously
been limited to tumors possessing a poorly differentiated
phenotype [10,44]. Using integrative genomics and experimental
data, we here emphasize that Polycomb gene silencing is
associated with what is considered a differentiated plasmablast/
plasma cell tumor. In general, terminal differentiation is tightly
linked to an irreversible arrest in G1/G0 phase of the cell cycle
[45]. Our finding of the underexpressed gene signature in MM
suggests that Polycomb silencing enables expansion of differenti-
Polycomb Silencing in MM
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a differentiated phenotype. In acute leukemia cells, in which an
early block in differentiation leads to malignancy, LBH589 induces
differentiation [25]. It is therefore of interest to note that the
reduction of growth in MM by LBH589 is the result of cell cycle
arrest [39], fulfilling at least one of the criteria of differentiation.
Additional studies are required to dissect the functional role of the
repressed gene signature in maintaining proliferation in MM, and
the biological consequences of its reactivation.
The existence of the silenced gene expression profile in MGUS,
recently proposed to precede MM in majority of the cases
[46,47,48], suggests that aberrant Polycomb-mediated gene
silencing might be an early event during MM development.
Although a small subpopulation of clonogenic CD138 negative B
cells are suggested to function as cancer stem cells in MM [49],
they are unlikely to have an impact on the underexpressed gene
profile, when analyzing the tumor bulk. Instead, the identification
of the Polycomb-silenced gene profile in CD138 positive patient
samples and cell lines implies that this is a general feature shared
by a large proportion of the MM cells. The question, however,
remains if MM cells have acquired the Polycomb gene repression
signature de novo in the late stages of plasma cell differentiation, or
if it is a remnant from earlier stages of normal B-cell development,
which remains preserved in the MM cells. Though, currently we
cannot rule out any of these possibilities, our data argues that
maintaining a stemness feature in the plasma cell tumor is
important in order to sustain survival and self-renewal of MM.
Materials and Methods
Ethics Statements
The study involving human biopsy samples was conducted in
accordance with the Declaration of Helsinki and approved by the local
ethics committees of Stockholm and Uppsala (Dnr 2004:M-332).
Patients gave written informed consent for the sample collection.
In the animal studies animals had free access to food and water
and they were housed and treated following the conditions
approved by the Ethical Committee for Animal Experiments,
VUB (license nr LA1230281).
Bioinformatic mining
Publically available microarray data were explored using the
Oncomine database [21]. Briefly, microarray data were log-
transformed, median centered per array, and standard deviation
normalized to one per array. Genes underexpressed in MM
datasets were compared to literature defined concepts in
Oncomine, using the built in t-statistics.
Gene-set enrichment analysis was performed using the GSEA
v2.05 software from Broad Institute as previously described [50].
The five selected target genes (CIITA, CXCL12, GATA2, CDH6
and ICSBP/IRF8) were compared with the Mayo clinic data set
from Gene Expression Omnibus (GSE6477). The Mayo clinic
dataset contains 15 normal bone marrows that were compared to
147 different grades of MM patients.
Purification of MM cells from patient material and MM
cell lines
Heparinised bone marrow samples were obtained from 4 newly
diagnosed MM patients. Mononuclear cells were separated by Ficoll-
Paque Plus density sedimentation (Amersham Biosciences, Little
Chalfont, UK) and were subjected to CD138 immunomagnetic
purification according to the manufacturer’s protocol (Miltenyi
Biotech, Paris, France). The enriched fraction gave a purity of greater
than 95%, determined by May-Gru ¨nwald-Giemsa staining.
TheMM cell linesRPMI 8226 [51] and U-266-1984 [52] (source
ATCC and Kenneth Nilsson, Uppsala University, respectively)
were maintained in RPMI-1640 AQmedia
TM (SigmaH) supple-
mented with 10% fetal bovine serum (FBS, SigmaH) and antibiotics
(penicillin 100 U/ml and streptomycin 50 mg/ml; SigmaH)a t3 7 uC
in a humidified 5% CO2 in-air atmosphere. Exponentially growing
cells were seeded at 2610
5 cells/ml (RPMI 8226) or 4610
5 (U-266-
1984) and incubated overnight before addition of reagents.
Reagents
LBH589 (Panobinostat, Novartis Pharmaceuticals Inc.) was
dissolved in dimethyl sulfoxide (DMSO) and DZNep (National
Cancer Institute, Bethesda, MD, USA) was dissolved in dH2O.
Both chemical inhibitors were used at the indicated concentra-
tions. The concentration of solvent (DMSO or dH2O) in each
experiment (,0.1%) did not alter the growth and survival of the
MM cells (data not shown).
Chromatin immunoprecipitation (ChIP)
Proteins were cross-linked to DNA using 1% formaldehyde in
serum-free medium for 10 min in room temperature. Cross-
linking was inhibited by 125 mM glycine. Cells were washed in
ice-cold phosphate-buffered saline (PBS), treated with cell lysis
buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% NP-40 and
protease inhibitors) for 10 min on ice and cell nuclei were collected
at 2500 rpm for 5 min. Nuclei were lysed in RIPA buffer (MOPS
(free acid), 0.5 M EDTA pH 8.0, 5N NaCl (to adjust pH to 7.0–
7.2), 1% SDS; 10% NP-40, 10% DOC and protease inhibitors) for
10 min on ice and sonicated 3615 min (30 sec ON/30 sec OFF)
at ultrasonic wave output power 320 W in BioruptorH (Diagenode,
Lie `ge, Belgium). Chromatin was collected at 14 000 rpm for
15 min and divided in several fractions. Antibodies used were:
anti-H3K9ac (Millipore, 06-942), anti-H3K27me3 (Millipore, 07-
449) and IgG (Negative control, OneDay ChIP Kit
TMDiagenode).
Chromatin immunoprecipitation was performed using OneDay
ChIP Kit
TM (Diagenode, Lie `ge, Belgium) according to the
manufacturer’s protocol. Precipitated DNA was analyzed by Real
Time-qPCR using PlatinumH SYBRH Green qPCR SuperMix
UDG with Rox (Invitrogen, Carlsbad, CA) and 0.3 mM of each
forward and reverse primers. Primer sequences are given in
supplementary data (Table S2). The PCR conditions were: 95uC
for 2 min followed by 40 cycles of 95uC for 0:30 min and 60uC for
1 min. The run and analysis were performed using Mx3005P
instrument and software (Stratagene).
RNA extraction, cDNA synthesis and Quantitative Real-
Time RT-PCR
Total RNA was extracted using TRIzolH (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. Reverse transcrip-
tion using random primers (Invitrogen) was performed on 1–2 mg
of total RNA using SuperScript
TM III Reverse Transcriptase
(Invitrogen) according to the manufacturer’s protocol.
Each independent quantitative real-time reverse transcriptase
PCR (qRT-PCR) reaction contained 5 ng of cDNA, TaqManH
Gene Expression Master Mix (Applied Biosystems, Foster City,
CA) and TaqManH Gene Expression Assays (Applied Biosystems)
according to manufacturer’s recommendations. The run and
analysis were performed using Mx3005P instrument and software
(Stratagene).
Western Blot
At the indicated time points, RPMI 8226 and U-266-1984 cells
were harvested, washed with ice-cold PBS and resuspended in lysis
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5 mM EDTA and protease inhibitors (1 mM ZnCl2, 50 mM
Na2MoO4, 10 mM NaF, 0.1 mM NaVO3, 1 mM PMSF, 1 mM
DTT, 16 complete EDTA-free protease inhibitor (Roche,
Mannheim, Germany). Cell lysates were collected at 13 0006 g
for 10 minutes at 4uC. Proteins were fractionated on NuPAGEH
NovexH Bis-Tris gels (Invitrogen, Carlsbad, CA) and transferred
onto a nitrocellulose membrane using the iBlotH system (Invitro-
gen). The membrane was blocked in 5% non-fat dry milk in TBS
(10 mM Tris-HCl, pH 7.7, 150 mM NaCl) with 0.1% Tween 20
(TTBS) at room temperature for 1 hour, incubated with the
indicated primary antibodies overnight at 4uC, washed in TTBS
and incubated for 1 hour at room temperature with the
corresponding secondary HRP-conjugated antibodies (Amersham
Biosciences) in 5% non-fat dry milk in TTBS. Proteins were
visualized using ECL Plus
TM Chemiluminescent Detection
System. Primary antibodies used were: anti-EZH2 (AC22;
#3147, Cell Signaling Technology) and anti-Actin (I-19; sc-
1616, Santa Cruz Biotechnology).
Resazurin assay
RPMI 8226 and U-266-1984 cells were incubated in round
bottomed (RPMI 8226) or flat bottomed (U-266-1984) 96-well
plates with different concentrations of LBH589 or DZNep. At the
indicated time points, 10% AlamarBlue was added to the wells,
followed by incubation for 1–3 hours at 37uC in a humidified 5%
CO2 in-air atmosphere. Wallac VICTOR Multilabel Counter
(Wallac, Turku, Finland) was used for the fluorescence analysis.
Resazurin was excited at 530 nm and emitted light was measured
at 590 nm. Mean was calculated from triplicate wells and
subtracted from mean of blank wells resulting in DFluorescence.
The relative number of viable cells was expressed as percentage of
untreated cells and calculated as 1006 DFluorescence (treated
cells)/DFluorescence (untreated cells).
Apoptosis assay
RPMI 8226 and U-266-1984 were cultured in 6-well plates for
48 and 72 hours in the presence of LBH589 or DZNep. Apoptosis
was quantified by Annexin V (AV)-fluorescein isothocyanate
(FITC) and PI staining using TACS Annexin V-FITC Apoptosis
Kit (R&D Systems, Gaithersburg, MD, USA). Samples were
treated according to manufacturer’s recommendations and
analyzed by flow cytometry (FACScan), presenting apoptotic cells
as Annexin V-positive/PI-negative cells and necrotic cells as
Annexin V-positive/PI-positive cells.
Animals
C57BL/KaLwRij mice were purchased from Harlan CPB
(Horst, The Netherlands). Mice were used at 6 to 10 weeks of age.
5T33MMvv cells
At day 0 C57BL/KalwRij mice were injected with 0.5610
6
5T33MM cells. After 14 days mice were either assigned to a
treatment group receiving 10 mg/kg LBH589 (n=4; daily i.p.
injection) or to a vehicle group receiving 0.9% NaCl solution
(n=4; daily i.p. injection). After 5 days of treatment mice were
sacrificed and the BM harvested after flushing out of the femurs
and tibiae and crushing out of the vertebrae. The BM cells were
suspended in serum-free medium (RPMI 1640; Cambrex,
Europe), supplemented with penicillin-streptomycin, glutamine,
and minimal essential medium (MEM) nonessential amino acid
(NEAA)–pyruvate (Gibco, Life Technologies) and purified by
Lympholyte M (Cedarlane, Hornby, ON, Canada) gradient
centrifugation at 1000 g for 20 minutes, generating enriched
5T33MM cells.
For further enrichment, a negative selection for CD11b positive
cells was performed using a MidiMACS magnetic cell separator,
LD separation columns and CD11b magnetic microbeads (all
from Miltenyi Biotec, Bergisch Gladbach, Germany). 5T33MMvv
cells at a concentration of 10
7 cells per 90 ml MACS buffer
(phosphate buffered saline containing 0.5% bovine serum albumin
and 2 nM EDTA, pH 7.2) and 10 ml CD11b Microbeads were
incubated at 4uC for 15 min. The 5T33MMvv-microbeads
mixture was then loaded onto a separation column placed on
the magnetic cell separator. After the flow through, the column
was washed three times using 500 ml of MACS buffer and the
eluted cell fraction was collected for further experiments.
Assessment of the tumor burden in vivo
The 5T33MM cells were injected in C57BL/KalwRij mice as
described above. At day 0 mice were either assigned to a treatment
group receiving 10 mg/kg LBH589 (n=10; daily i.p. injection), to
a vehicle group receiving 0.9% NaCl solution (n=10; daily i.p.
injection) or to an untreated, disease-free group (n=10) as a
control group. The animals were sacrificed when they showed
signs of morbidity (paralysis). Tumor load was analyzed by means
of serum paraprotein concentration and BM plasmocytosis: the
first was quantified by electrophoresis and assessment of total
protein, the latter by quantification of May Gru ¨nwald-Giemsa
staining of BM cytospin samples.
Survival analysis
Survival was studied using Kaplan-Meier analysis. 5T33MM
cells were injected as above and at day 0 mice received 10 mg/kg
LBH589 (n=12; daily i.p. injection) or vehicle, 0.9% NaCl
solution (n=12; daily i.p. injection). An untreated disease-free
group (n=12) was used as a control. Each mouse was sacrificed
when it showed signs of morbidity (paralysis).
Supporting Information
Figure S1 The PRC2 components EED, EZH2 and SUZ12 are
overexpressed in MM. (A): MM patients (n=74) compared to
plasma cells (n=37) and tonsillar tissue (n=37) (Zhan, Hardin et
al. 2002). (B): Smoldering Myeloma patients (n=12) compared to
MGUS patients (n=44) and normal bone marrow (n=22) (Zhan,
Barlogie et al. 2007). (C): MM stage III patients (n=34) compared
to MM stage I (n=30) and stage II (n=38) (Agnelli, Fabris et al.
2007). Analysis was performed on normalized expression units,
using the built in t-statistics (Rhodes, Yu et al. 2004).
Found at: doi:10.1371/journal.pone.0011483.s001 (0.99 MB TIF)
Figure S2 The PRC2 targets CIITA, GATA2, CDH6,
CXCL12 and ICSBP/IRF8 are underexpressed in MM. Target
genes were defined by Bracken et al. (Bracken, Dietrich et al. 2006)
in embryonic fibroblasts and their expression pattern examined
using Oncomine. (A): MM patients (n=74) compared to plasma
cells (n=37) and tonsillar tissue (n=37) (Zhan, Hardin et al.
2002). (B): Smoldering Myeloma patients (n=12) compared to
MGUS patients (n=44) and normal bone marrow (n=22) (Zhan,
Barlogie et al. 2007). (C): MM stage III patients (n=34) compared
to MM stage I (n=30) and stage II (n=38) (Agnelli, Fabris et al.
2007). Analysis was performed on normalized expression units,
using the built in t-statistics (Rhodes, Yu et al. 2004).
Found at: doi:10.1371/journal.pone.0011483.s002 (1.51 MB TIF)
Figure S3 The H3K27-tri-methylated CIITA, GATA2, CDH6,
CXCL12 and ICSBP/IRF8 are enriched among genes under-
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enrichment (GSE) analysis of the five PRC2 target genes (CIITA,
GATA2, CDH6, CXCL12 and ICSBP/IRF8) when compared to
Mayo clinic dataset (Chng, Kumar et al. 2007) (GSE6477) using
software GSEA v 2.05 with FDR q-value 0.0181.
Found at: doi:10.1371/journal.pone.0011483.s003 (0.68 MB TIF)
Figure S4 DZNep and LBH589 deplete EZH2 protein
expression in a concentration-dependent manner. (A): The RPMI
8226 cells and (B): The U-266-1984 cells were treated for 48 hours
with 0.5, 2.5 and 10 mM DZNep; (C): the RPMI 8226 cells were
treated for 72 hours with 4, 10 and 20 nM LBH589 and (D): the
U-266-1984 cells were treated for 24 hours with 4, 20 and 100 nM
LBH589 followed by western blot analysis using anti-EZH2
antibody. Actin was used to control for equal loading.
Found at: doi:10.1371/journal.pone.0011483.s004 (0.14 MB TIF)
Figure S5 DZNep and LBH589 reduce growth of the RPMI
8226 and U-266-1982 cells. (A) and (B): RPMI 8226 and U-266-
1984 were treated with the indicated concentrations of DZNep
(48 hours) and LBH589 (24 hours) followed by AlamarBlue assay.
At least 2 experiments were performed in triplicates; data are
presented as mean percentage of control 6SD.
Found at: doi:10.1371/journal.pone.0011483.s005 (0.08 MB TIF)
Figure S6 DZNep and LBH589 have mild effect on growth of
the normal SK 1064 cells and PBMC. (A) and (B): SK 1064 and
PBMC were treated with the indicated concentrations of DZNep
(48 hours) and LBH589 (48 hours) followed by resazurin assay.
Experiment was performed in triplicates; data are presented as
mean percentage of control 6SD. Peripheral blood mononuclear
cells (PBMC) were isolated by Ficoll-Hypaque separation of buffy
coats from healthy donors.
Found at: doi:10.1371/journal.pone.0011483.s006 (0.09 MB TIF)
Table S1 H3K27me3 targets among the 10% most under
expressed genes in MM, MGUS and MM stage III, corresponding
to figure 1a, 1b and 1c. Complete gene list of H3K27me3 targets
(Bracken, Dietrich et al. 2006) among the 10% most under
expressed genes in MM (Zhan, Hardin et al. 2002), MGUS (Zhan,
Barlogie et al. 2007) and MM stage III (Agnelli, Fabris et al. 2007),
corresponding to figure 1a, 1b and 1c.
Found at: doi:10.1371/journal.pone.0011483.s007 (0.33 MB
XLS)
Table S2 Primers used in real-time qPCR for chromatin
immunoprecipitation (ChIP). Primers used in real-time qPCR
for chromatin immunoprecipitation (ChIP).
Found at: doi:10.1371/journal.pone.0011483.s008 (0.03 MB
DOC)
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